2,303,030 Shares of Common Stock BIOXCEL THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • September 27th, 2019 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • New York
BioXcel Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell 2,303,030 shares (the “Firm Stock”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). In addition, the Company proposes to grant to the underwriters named in Schedule I (the “Underwriters”) attached to this agreement (this “Agreement”) an option to purchase up to 345,454 additional shares of the Common Stock on the terms set forth in Section 2 (the “Option Stock”). The Firm Stock and the Option Stock, if purchased, are hereinafter collectively called the “Stock”. This Agreement is to confirm the agreement concerning the purchase of the Stock from the Company by the Underwriters.
